Albireo Pharma Executives

ALBODelisted Stock  USD 44.15  0.75  1.67%   
Albireo Pharma employs about 130 people. The company is managed by 25 executives with a total tenure of roughly 140 years, averaging almost 5.0 years of service per executive, having 5.2 employees per reported executive. Analysis of Albireo Pharma's management performance can provide insight into the firm performance.
Ronald Cooper  CEO
President CEO, Director
David Chiswell  Chairman
Chairman of the Board
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Albireo Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.2494) % which means that it has lost $0.2494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9308) %, meaning that it created substantial loss on money invested by shareholders. Albireo Pharma's management efficiency ratios could be used to measure how well Albireo Pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Albireo Pharma Workforce Comparison

Albireo Pharma is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 88,374. Albireo Pharma adds roughly 130 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (2.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.15.

Albireo Pharma Notable Stakeholders

An Albireo Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Albireo Pharma often face trade-offs trying to please all of them. Albireo Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Albireo Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ronald CooperPresident CEO, DirectorProfile
David ChiswellChairman of the BoardProfile
Peter ZornSenior Vice President - Corporate Development, General Counsel and SecretaryProfile
Thomas SheaCFO, TreasurerProfile
Simon HarfordCFO, TreasurerProfile
Brian PereiraIndependent DirectorProfile
Davey ScoonDirectorProfile
Stephanie OkeyDirectorProfile
Anne KlibanskiDirectorProfile
Denise ScotsKnightDirectorProfile
Michael GutchDirectorProfile
Roger JeffsDirectorProfile
Heather PrestonDirectorProfile
Julia BrownIndependent DirectorProfile
Michelle GrahamChief OfficerProfile
Kristina TorfgardVP HeadProfile
Pamela MPHChief OfficerProfile
Jason DuncanGen OfficerProfile
Pamela StephensonChief Commercial OfficerProfile
Joan ConnollyChief OfficerProfile
Martha CarterChief Regulatory OfficerProfile
Jan MattssonMD OfficerProfile
Patrick HornChief Medical OfficerProfile
Paresh SoniChief Medical OfficerProfile
PerGoran GillbergCoFounder DevelProfile

About Albireo Pharma Management Performance

The success or failure of an entity such as Albireo Pharma often depends on how effective the management is. Albireo Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Albireo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Albireo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. Albireo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 130 people.
The data published in Albireo Pharma's official financial statements usually reflect Albireo Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Albireo Pharma. For example, before you start analyzing numbers published by Albireo accountants, it's critical to develop an understanding of what Albireo Pharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Albireo Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Albireo Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Albireo Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Albireo Pharma. Please utilize our Beneish M Score to check the likelihood of Albireo Pharma's management manipulating its earnings.

Albireo Pharma Workforce Analysis

Traditionally, organizations such as Albireo Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Albireo Pharma within its industry.

Albireo Pharma Manpower Efficiency

Return on Albireo Pharma Manpower

Revenue Per Employee312.1K
Revenue Per Executive1.6M
Net Loss Per Employee261.8K
Net Loss Per Executive1.4M
Working Capital Per Employee205.9K
Working Capital Per Executive1.1M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Find actively traded Exchange Traded Funds (ETF) in USA
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated